InMed Pharmaceuticals Files 8-K

Ticker: INM · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1728328

Inmed Pharmaceuticals INC. 8-K Filing Summary
FieldDetail
CompanyInmed Pharmaceuticals INC. (INM)
Form Type8-K
Filed DateDec 18, 2025
Risk Levellow
Pages3
Reading Time4 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-action, disclosure, financials

TL;DR

InMed Pharma dropped an 8-K on Dec 18th covering votes, Reg FD, and financials.

AI Summary

InMed Pharmaceuticals Inc. filed an 8-K on December 18, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. The filing pertains to events occurring on December 17, 2025, with the company's principal executive offices located in Vancouver, British Columbia.

Why It Matters

This 8-K filing indicates important corporate actions and disclosures by InMed Pharmaceuticals Inc., which could affect investor understanding of the company's governance and financial status.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of corporate events and does not appear to contain significant new risks.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in this excerpt.

What is the nature of the Regulation FD Disclosure?

The filing lists 'Regulation FD Disclosure' as an item, suggesting that the company is making public disclosures in compliance with Regulation Fair Disclosure, but the content of these disclosures is not detailed here.

When was the earliest event reported in this 8-K?

The earliest event reported in this 8-K was on December 17, 2025.

Where are InMed Pharmaceuticals Inc.'s principal executive offices located?

InMed Pharmaceuticals Inc.'s principal executive offices are located at Suite 1445 – 885 West Georgia Street, Vancouver, British Columbia, Canada V6C 3E8.

What is the company's SEC file number?

The SEC file number for InMed Pharmaceuticals Inc. is 001-39685.

Filing Stats: 942 words · 4 min read · ~3 pages · Grade level 9.8 · Accepted 2025-12-18 11:55:06

Filing Documents

07: Submission of Matters to a Vote of Security Holders

Item 5.07: Submission of Matters to a Vote of Security Holders. On December 17, 2025, InMed Pharmaceuticals Inc. (the "Corporation") held its 2025 Annual General and Special Meeting of Shareholders (the "Meeting"). At the Meeting, all items of business were voted upon by the shareholders, as indicated below: Proposal No. 1-Presentation of Financial Statements The Company's audited consolidated financial statements for the fiscal year ended June 30, 2025, including the related management's discussion and analysis and auditors report was presented to shareholders at the Meeting. No vote was taken with respect to the audited annual financial statements and receipt of the audited annual financial statements did not, and does not, constitute approval or disapproval of any matters referred to therein. Proposal No. 2-Election of Directors The Corporation's shareholders approved the election of five director nominees to the Corporation's board of directors (the "Board") to hold office until the 2026 Annual General Meeting of Shareholders or until their successors are elected or appointed. Results of the vote for the election of the Board at the Meeting are set out as follows: Director Votes For Withheld Votes Number Percentage Number Percentage Eric A. Adams 125,352 82.03% 27,469 17.98% Andrew Hull 125,315 82.00% 27,506 18.00% Nicole Lemerond 125,485 82.11% 27,336 17.89% Neil Klompas 125,444 82.09% 27,377 17.91% John Bathery 125,227 81.94% 27,594 18.06% Proposal No. 3-Appointment of Auditor The Corporation's shareholders voted at the Meeting to approve the appointment of CBIZ CPAs P.C as the independent registered public accounting firm of the Corporation until the 2026 Annual General Meeting of Shareholders or until a successor is named. Votes For % Votes For Votes Against Votes Abstained % Votes Abstained 1 Broker Non-Votes 783,232 78.84% 0 210,258 21.16% 1 2 Proposal No. 4-SEPA Sh

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 18, 2024, the Corporation issued a press release announcing the voting results of the Meeting and other related matters. A copy of the press release is furnished hereto as Exhibit 99.1. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, including, without limitation, any registration statement filed pursuant thereto, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit 99.1. Press release, dated December 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2025 INMED PHARMACEUTICALS INC. By: /s/ Eric A. Adams Name: Eric A. Adams Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing